Reduced Hospitalization Cost for Upper Gastrointestinal Events That Occur Among Elderly Veterans Who Are Gastroprotected

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 4, 2010, Pages 350-356

  Abraham, Neena S ^a,b   Hartman, Christine ^a,b   Hasche, Jennifer ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Administrative Database; Comparative Effectiveness; Department of Veterans Affairs; Gastrointestinal Hemorrhage; Health Resource Use

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CHOLINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE; ETODOLAC; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LANSOPRAZOLE; MECLOFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OXAPROZIN; PANTOPRAZOLE; PHENYLBUTAZONE; PIROXICAM; RABEPRAZOLE; ROFECOXIB; SALICYLIC ACID; SULINDAC; TOLMETIN; VALDECOXIB;

AGED; ARTICLE; COST BENEFIT ANALYSIS; DEMOGRAPHY; DRUG EXPOSURE; ECONOMIC ASPECT; FEMALE; HOSPITAL COST; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICARE; OUTPATIENT; PRESCRIPTION; VETERAN;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; PROTON PUMP INHIBITORS; SALICYLATES; VETERANS;

EID: 77949658275     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.01.002     Document Type: Article

References (39)

1. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528 2
2. Griffin M.R., Ray W.A., and Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 109 (1988) 359-363
3. Smalley W.E., Griffin M.R., Fought R.L., et al. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 11 (1996) 461-469
4. Recommendations for the medical management of osteoarthritis of the hipknee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 43 (2000) 1905-1915
5. Lanza F.L. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 93 (1998) 2037-2046
6. Abraham N.S., El-Serag H.B., Johnson M.L., et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 129 (2005) 1171-1178
7. Abraham N.S., Hartman C., Castillo D., et al. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol 103 (2008) 323-332
8. Goldstein J.L., Howard K.B., Walton S.M., et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 4 (2006) 1337-1345
9. Scheiman J.M., Yeomans N.D., Talley N.J., et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 101 (2006) 701-710
10. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347 (2002) 2104-2110
11. Chan F.K. Management of high-risk patients on non-steroidal anti-inflammatory drugs or aspirin. Drugs 66 Suppl 1 (2006) 23-28
12. Rahme E., Bardou M., Dasgupta K., et al. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology (Oxford) 46 (2007) 265-272
13. Pilotto A., Franceschi M., Leandro G., et al. NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies. Drugs Aging 20 (2003) 701-710
14. Pilotto A., Franceschi M., Leandro G., et al. The risk of upper gastrointestinal bleeding in elderly users of aspirin and other non-steroidal anti-inflammatory drugs: the role of gastroprotective drugs. Aging Clin Exp Res 15 (2003) 494-499
15. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 127 (2004) 1038-1043
16. Lai K.C., Chu K.M., Hui W.M., et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118 (2005) 1271-1278
17. Lloyd S.S., and Rissing J.P. Physician and coding errors in patient records. JAMA 254 (1985) 1330-1336
18. Page W.F., Mahan C.M., and Kang H.K. Vital status ascertainment through the files of the Department of Veterans Affairs and the Social Security Administration. Ann Epidemiol 6 (1996) 102-109
19. Wagner T.H., Chen S., and Barnett P.G. Using average cost methods to estimate encounter-level costs for medical-surgical stays in the VA. Med Care Res Rev 60 3 Suppl (2003) 15S-36S
20. Barnett P.G. Review of methods to determine VA health care costs. Med Care 37 4 Suppl Va (1999) AS9-AS17
21. Abraham N.S., Castillo D.L., and Hartman C. National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent NSAID use. Aliment Pharmacol Ther 28 (2008) 97-106
22. Abraham N.S., Cohen D.C., Rivers B., et al. Validation of administrative data used for the diagnosis of upper gastrointestinal events following nonsteroidal anti-inflammatory drug prescription. Aliment Pharmacol Ther 24 (2006) 299-306
23. Goodman C., Cronin K., and Gemmen E. The burden of gastrointestinal diseases (2001), The American Gastroenterological Association, Bethesda, MD
24. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992) 613-619
25. HCUPnet, Healthcare Cost and Utilization Project (2006), Agency for Healthcare Research and Quality, Rockville, MD. http://hcupnet.ahrq.gov Accessed December 11, 2009
26. Rahme E., Toubouti Y., and LeLorier J. Utilization and cost comparison of current and optimal prescribing of nonsteroidal antiinflammatory drugs in Quebec, Canada. J Rheumatol 33 (2006) 588-596
27. El Serag H.B., Graham D.Y., Richardson P., et al. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. Arch Intern Med 162 (2002) 2105-2110
28. Fendrick A.M. Cost-effective use of NSAIDs: issues pertinent to coxib use in managed care. Am J Manag Care 8 17 Suppl (2002) S529-S541
29. Fendrick A.M., Bandekar R.R., Chernew M.E., et al. Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis. Arthritis Rheum 47 (2002) 36-43
30. Marshall J.K., Pellissier J.M., Attard C.L., et al. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. Pharmacoeconomics 19 (2001) 1039-1049
31. Bloom B.S. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 84 (1988) 20-24
32. Laine L., Wogen J., and Yu H. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs. Gastroenterology 125 (2003) 389-395
33. Lanes S.F., Lanza L.L., Radensky P.W., et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum 40 (1997) 1475-1481
34. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 241-249
35. Smith M.W., and Joseph G.J. Pharmacy data in the VA Health Care System. Medical care research and review 60 (2003) 92S-123S
36. Landis N.T. Medicare pays twice the VA cost for drugs, report says. Am J Health Syst Pharm 56 (1999) 313
37. Wilcox C.M., Allison J., Benzuly K., et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol 4 (2006) 1082-1089
38. Taha A.S., McCloskey C., Prasad R., et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 374 (2009) 119-125
39. Wilcox C.M. Older and cheaper may still be good. Clin Gastroenterol Hepatol 7 (2009) 1024